Beta Bionics, Inc. (BBNX)Healthcare | Medical Devices | Irvine, United States | NasdaqGM
19.72 USD
+0.18
(0.921%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 20.11 +0.39 (1.978%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:13 a.m. EDT
Beta Bionics presents a classic value trap scenario where the business fundamentals are deteriorating despite a technically resilient recent price bounce. While the stock has rallied recently, closing near $19 after a period of weakness, the underlying reality is stark: the company is burning cash aggressively with negative operating cash flow of -$55.8 million and free cash flow of -$40.3 million. More critically, the operational narrative is breaking down, highlighted by headlines regarding a 'deceleration in new patient starts' and a recent miss on revenue estimates. This operational drag is likely the catalyst for the heavy put positioning seen in the options chain, where traders are locking in downside protection at strikes significantly below current prices. The short-term outlook remains murky. The recent price action shows some life, trading above its 50-day average, which provides a temporary floor. However, the statistical forecasting model offers no directional bias, reflecting the high volatility and lack of clear trend. Without a reversal in the patient acquisition curve or a path to profitability, this rally risks being a dead cat bounce. The long-term investment case is currently neutral-to-negative due to the multi-year trajectory of declining performance and the absence of a fortress balance sheet; the company is not generating enough cash to sustain operations without dilution or external financing. There are no dividends to provide income, making this a pure speculation on a turnaround that the current data does not yet support. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.174929 |
| AutoETS | 0.174934 |
| MSTL | 0.179623 |
| AutoTheta | 0.184049 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 6.27 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.197 |
| Excess Kurtosis | -1.23 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.54 |
| Revenue per Share | 2.689 |
| Market Cap | 887,196,608 |
| Forward P/E | -8.52 |
| Profit Margins | -61.31% |
| Website | https://www.betabionics.com |
As of Aug. 22, 2026, 4:13 a.m. EDT: Speculators are overwhelmingly positioning for downside protection, evidenced by massive open interest in deep out-of-the-money puts expiring in October 2026 (strikes at $10 and $15) and zero put volume for later dates. Conversely, call activity is sparse and concentrated near the money, with significant open interest at the $20 strike acting as a resistance anchor. The lack of speculative call volume beyond the immediate expiration suggests a market consensus expecting stagnation or a decline rather than a breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.036803365 |
| Address1 | 11 Hughes |
| All Time High | 32.71 |
| All Time Low | 8.8 |
| Ask | 17.63 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 1,123,810 |
| Average Daily Volume3 Month | 1,166,092 |
| Average Volume | 1,166,092 |
| Average Volume10Days | 1,123,810 |
| Bid | 10.42 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 5.699 |
| City | Irvine |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 19.72 |
| Current Ratio | 8.88 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 20.07 |
| Day Low | 19.25 |
| Debt To Equity | 2.54 |
| Display Name | Beta Bionics |
| Earnings Call Timestamp End | 1,785,355,200 |
| Earnings Call Timestamp Start | 1,785,355,200 |
| Earnings Timestamp | 1,785,355,200 |
| Earnings Timestamp End | 1,793,131,200 |
| Earnings Timestamp Start | 1,793,131,200 |
| Ebitda | -80,799,000 |
| Ebitda Margins | -0.67891 |
| Enterprise To Ebitda | -8.827 |
| Enterprise To Revenue | 5.993 |
| Enterprise Value | 713,219,648 |
| Eps Current Year | -1.895 |
| Eps Forward | -2.315 |
| Eps Trailing Twelve Months | -1.61 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 16.6496 |
| Fifty Day Average Change | 3.0704002 |
| Fifty Day Average Change Percent | 0.18441287 |
| Fifty Two Week Change Percent | 3.6803365 |
| Fifty Two Week High | 32.71 |
| Fifty Two Week High Change | -12.99 |
| Fifty Two Week High Change Percent | -0.39712626 |
| Fifty Two Week Low | 8.8 |
| Fifty Two Week Low Change | 10.919999 |
| Fifty Two Week Low Change Percent | 1.240909 |
| Fifty Two Week Range | 8.8 - 32.71 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,738,247,400,000 |
| Float Shares | 26,435,041 |
| Forward Eps | -2.315 |
| Forward P E | -8.518358 |
| Free Cashflow | -40,294,000 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 420 |
| Fullday Change | 0.179998 |
| Fullday Change Percent | 0.921179 |
| Fullday Price | 20.11 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.58314997 |
| Gross Profits | 69,402,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01079 |
| Held Percent Institutions | 1.12089 |
| Implied Shares Outstanding | 44,989,688 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ipo Expected Date | 2,025-01-30 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California. |
| Long Name | Beta Bionics, Inc. |
| Market | us_market |
| Market Cap | 887,196,608 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_365537151 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -72,973,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 879,548,400 |
| Number Of Analyst Opinions | 11 |
| Open | 19.47 |
| Operating Cashflow | -55,810,000 |
| Operating Margins | -0.79899 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 949 427 7785 |
| Post Market Change | 0.3900013 |
| Post Market Change Percent | 1.9776943 |
| Post Market Price | 20.11 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 19.54 |
| Price Eps Current Year | -10.406332 |
| Price Hint | 2 |
| Price To Book | 3.460256 |
| Price To Sales Trailing12 Months | 7.4546194 |
| Profit Margins | -0.61315 |
| Quick Ratio | 7.716 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.75 |
| Region | US |
| Regular Market Change | 0.179998 |
| Regular Market Change Percent | 0.921179 |
| Regular Market Day High | 20.07 |
| Regular Market Day Low | 19.25 |
| Regular Market Day Range | 19.25 - 20.07 |
| Regular Market Open | 19.47 |
| Regular Market Previous Close | 19.54 |
| Regular Market Price | 19.72 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 992,332 |
| Return On Assets | -0.16674 |
| Return On Equity | -0.26155 |
| Revenue Growth | 0.378 |
| Revenue Per Share | 2.689 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 44,989,688 |
| Shares Percent Shares Out | 0.1666 |
| Shares Short | 7,494,706 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 6,609,679 |
| Short Name | Beta Bionics, Inc. |
| Short Percent Of Float | 0.1674 |
| Short Ratio | 5.53 |
| Source Interval | 15 |
| State | CA |
| Symbol | BBNX |
| Target High Price | 30.4 |
| Target Low Price | 14.0 |
| Target Mean Price | 20.30909 |
| Target Median Price | 20.0 |
| Total Cash | 180,488,992 |
| Total Cash Per Share | 4.012 |
| Total Debt | 6,512,000 |
| Total Revenue | 119,013,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.61 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 16.939526 |
| Two Hundred Day Average Change | 2.7804737 |
| Two Hundred Day Average Change Percent | 0.16414118 |
| Type Disp | Equity |
| Volume | 992,332 |
| Website | https://www.betabionics.com |
| Zip | 92,618 |